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The effectiveness of dapagliflozin in the management of type-2 diabetes mellitus (T2-DM) is an essential 
issue for establishing a basis for prescribing dapagliflozin. This study aimed to assess the effectiveness of 
dapagliflozin in combination with other hypoglycemic agents (OHAs) in reducing glycated hemoglobin 
(HbA1c) and fasting blood glucose (FBG) at 3, 6, 9 and 12 months. This retrospective observational 
study included all patients who visited the endocrine clinics at Hamad Medical Corporation (HMC) and 
were treated with dapagliflozin. Demographics and laboratory data were obtained retrospectively from 
computerized patient medical profiles (eMR-viewer). The main outcome measures were the differences 
in HbA1c and FBG from baseline at different months. Eighty-one Qatari patients were found to have 
received dapagliflozin during the study period; 72% of them (n = 58) were males, with a mean age of 
57.0 ± 9.0 years and a mean baseline HbA1c of 9.0 ± 1.4%. Administration of dapagliflozin as an add-on 
therapy was found to decrease HbA1c significantly by 0.8 percentage point after 6 months (P = 0.006) 
and by 1.5 percentage point after 12 months (P = 0.062). FBG was significantly reduced at 6 months and 9 
months (P = 0.001 and P = 0.03, respectively). Dapagliflozin effectively reduced the HbA1c level and FBG 
when used in combination with other OHAs or insulin within 6 to 12 months.
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a new class of oral antihyperglycemic drugs 
with an innovative mechanism of action, and is the second SGLT2 inhibitor to be approved by the Food and Drug 
Administration of the United States of America (FDA). Managing type 2-diabetes mellitus (T2-DM) with effec-
tive and tolerable oral agents will eventually decrease the devastating complications associated with uncontrolled 
T2-DM and ultimately improve quality of life. In 1990, a novel class of drugs to treat T2-DM with glucose urea 
was developed but was limited by poor bioavailability due to poor absorption as well as rapid degradation1–3. This 
discovery opened the gate for a promising group of drugs for the treatment of T2-DM, SGLT2 inhibitors, and this 
group includes canagliflozin, which became the first SGLT2 inhibitor approved by the FDA, followed by dapagli-
flozin, which was approved by the FDA on January 8, 20144,5.
SGLT2 localizes almost exclusively to the kidney proximal tubules, where it reabsorbs most of the ~180 g 
of glucose that is filtered through the glomeruli each day6. In diabetic patients, the SGLT2 cotransporters are 
significantly upregulated, increasing glucose reabsorption and leading to glucose conservation and prolonged 
hyperglycemia. Dapagliflozin is a highly selective and reversible inhibitor of SGLT2 that acts by inhibiting tubu-
lar reabsorption of up to half of the glucose filtered by SGLT2 located at segments 1 and 2 in the proximal renal 
tubule, resulting in a dose-dependent increase in urinary glucose excretion and ultimately, an improvement in 
glycemic parameters7–10. Its C-aryl glucoside-derived chemical structure provides dapagliflozin with a prolonged 
pharmacokinetic half-life as well as a nearly 3000-fold selectivity for SGLT2 versus SGLT1, making it possible to 
administer dapagliflozin in an unmodified oral form without affecting SGLT-1-mediated glucose transport in 
other tissues11–14.
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This mechanism of action provides us with a valuable clue: dapagliflozin does not act through increasing 
insulin secretion or decreasing insulin receptor resistance, and thus, commencing therapy with this group of 
agents neither causes hypoglycemia nor depends on the duration of T2-DM. It can be initiated as monotherapy 
in newly diagnosed patients or in combination with other oral agents or insulin in patients with long-standing 
diabetes15,16. However, the glucosuria induced by SGLT-2 inhibition might be attributed to hypoglycemia, UTIs, 
or genital infections17.
The efficacy of this novel group of medications requires extensive evaluation in different populations and with 
different regimens to establish the best practice for managing T2-DM18,19. Many studies have evaluated SGLT2 
inhibitors and confirmed the efficacy of dapagliflozin. Some studies demonstrated its effectiveness as monother-
apy for newly diagnosed patients with T2-DM13,20–24. Other groups of studies asserted its effectiveness in combi-
nation with other oral hypoglycemic agents19,25–28. Moreover, when dapagliflozin was used in conjunction with 
insulin, studies reported the same level of efficacy with an additional benefit of decreasing insulin demand28–30. 
Of note, dapagliflozin efficacy was well established over a wide range of populations, predominantly in Western 
populations. Yang et al. found that dapagliflozin as an add-on to insulin, with or without oral antidiabetic drugs 
(OADs) in Asian patients, significantly improved glycemic control31. However, to date, there is very few study that 
has examined the effectiveness of this group of medications in a Middle Eastern population, which has different 
genetic characteristics20,32,33 in addition to unique demographic, culture and lifestyle characteristics15,34–38. All 
these variables may alter the response to SGLT2 inhibitors in general and specifically dapagliflozin.
This study aims to assess the effectiveness of dapagliflozin in the management of T2-DM in combination with 
other hypoglycemic agents (OHAs) or insulin, in terms of improving HbA1c and fasting blood glucose, among 
diabetic patients in Qatar. Almost all medicines in Qatar are imported, and the use of the brand originator is high. 
Thus, establishing evidence of the effectiveness of each medicine in the formulary is important. The results of 
this study will establish the efficacy of dapagliflozin in the management of T2-DM in Qatar in particular and the 
Middle East in general.
Results
Patient’s profile. All eighty-one patients were Qataris with a mean age of 57 ± 9 years; of the patients, 72% 
were male. The mean HbA1c and fasting blood glucose at baseline were 9.2 ± 1.4% and 11 ± 4 mmol/L, respec-
tively (Table 1).
Common diabetic treatment combinations. In this study, all patients received dapagliflozin as an 
add-on therapy in combination with standard diabetic treatment. They were divided into 4 treatment groups 
based on the most common combinations, and their baseline readings for HbA1c and fasting blood glucose 
(FBG) were equivalent (p = 0.13 and p = 0.67, respectively) (Table 2).
HbA1c and FBG levels at the follow-up period. In the follow-up period, repeated measures ANOVA 
was used to evaluate the difference in HbA1c and FBG following treatment with dapagliflozin. Only values from 
the 3- and 6-month follow-ups were included, as the number of patients who had data at all time points was very 
small. Although the overall p-values for the changes in HbA1c and FBG from baseline were significant (p = 0.026 
& p = 0.013, respectively) (Table 3), the HbA1c value was significantly lowered from the baseline starting only at 
the 6-month follow-up (p = 0.045). Similarly, FBG began to decrease significantly at 6 months (p = 0.019).
Demographics n (%) Mean (SD)
Gender
   Male 58 (72.0)
   Female 23 (28.0)
Nationality
   Qatari 81 (100)
   non-Qatari 0 (0)
Age 58 (8.6)
HbA1c 9.2 (1.4)
FBG 11 (4.0)
Co-medications
   Metformin 53 (65.0)
   Pioglitazone 5 (6.2)
   Gliclazide 23 (28.4)
   Glimepiride 15 (18.5)
   Glibenclamide 1 (1.2)
   Repaglinide 1 (1.2)
   Acarbose 1 (1.2)
   Insulin 36 (51.9)
   Vildagliptin 6 (7.4)
   Liraglutide 16 (19.9)
Table 1. The demographic and clinical characteristics of patients at baseline.
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Changes in HbA1c and FBG from baseline among the different 4 groups. Administration of 
dapagliflozin was found to reduce HbA1c significantly after 6 months by 1 percentage point (p = 0.045) and 
showed a decreasing trend after 12 months of 1.5 percentage points (p = 0.062). Moreover, FBG was markedly 
reduced at 6 months and 9 months (p = 0.001 and p = 0.03, respectively). With further analysis of data from 
follow-up at 9 and 12 months, the mean HbA1c was reduced by greater values, 1.1 ± 1.4%, and 1.5 ± 2%, respec-
tively; however, these values failed to reach statistical significance (p = 0.88 & p = 0.63, respectively). Likewise, 
the FBG level was reduced by larger values from 11.0 ± 2.0 mmol/L to 8.0 ± 1.8 mmol/L at 12 months, which 
could be of clinical importance although not statistically significant (p = 0.7). Notably, the HbA1c (Table 4) and 
FBG (Table 5) values within the 4 different treatment groups tended to decrease over the 12-month period but 
failed to reach statistical significance. Even the between-group differences in the HbA1c and FBG readings were 
statistically nonsignificant.
Discussion
The 2017 American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology 
(ACE) comprehensive glycemic control algorithm has placed SGLT2 inhibitors before DPP4 inhibitors in the 
hierarchical order of recommended use as monotherapy as well as add-on therapy39. This study was carried out to 
provide clinicians with research evidence on the use of dapagliflozin and its effectiveness in the management of 
T2-DM in combination with OHAs or insulin. The findings can be incorporated into their professional judgment 
and clinical decision-making.
Sufficient evidence demonstrates that many T2-DM patients do not achieve their glycemic goals40. T2-DM is 
a progressive chronic disease, and over time, its treatment requires intensification. Dapagliflozin has a different 
mechanism of action. According to Fioretto et al., dapagliflozin is completely insulin-independent and efficacious 
Treatments 
groups: N (%) Medications
A1c (%) at baseline 
Mean (sd)
FBG (mmol/L) at 
baseline Mean (sd)
Group 1: 16 (19.8) Dapagliflozin + Metformin + Sulfonylureas (SUs) +/− DDP4i 9.2 11.8
Group 2: 27 (33.3) Dapagliflozin + Metformin + DDP4i +/− Insulin 9.9 9.3
Group 3: 10 (12.3) Dapagliflozin + Insulin + others 10.7 13.6
Group 4: 28 (34.6) Other combinations Dapagliflozin + (Acarbose, Repaglinide, Liraglutide or Pioglitazone) 9.6 12.6
Table 2. The common diabetic treatment combinations.
Outcome measures Baseline (mean/sd) At 3 months (mean/sd) At 6 months (mean/sd) p value
HbA1c* 9.8 ± 0.4% 9.2 ± 0.35% 8.8 ± 0.27% 0.026
FBG** 11.4 ± 3.6 mmol/L 9.8 ± 4 mmol/L 8.5 ± 2 mmol/L 0.013
Table 3. HbA1c and FBG levels at baseline and 3 & 6 months posttreatment. *HbA1c baseline to 3 months; 
p = 0.48. **FBG baseline to 3 months; p = 0.63. HbA1c baseline to 6 months; p = 0.045. FBG baseline to 6 
months; p = 0.019. HbA1c 3 months to 6 months; p = 0.45. FBG 3 months to 6 months; p = 0.311.
Treatment 
group
Baseline 
HbA1c (%)
After 3 
months
After 6 
months*
After 9 
months
After 12 
months P value
Group 1 9.2 (0.64) 8.8 (1.7) 8.4 (1.3) 8.1 (1.2) 8.2 (1.4) >0.05
Group 2 9.9 (1.6) 8.5 (1.0) 8.8 (1.6) 7.5 (1.7) 7.5 (2.0) >0.05
Group 3 10.8 (3.2) 9.2 (0.3) 9.7 (0.7) 9.1 (1.3) 8.5 (1.0) >0.05
Group 4 9.6 (1.3) 9.8 (1.6) 8.5 (0.6) 7.5 (1.0) 7.9 (1.1) >0.05
Table 4. The change in HbA1c from baseline among the different treatment groups. Baseline to 6 months 
between-groups change in HbA1c (P = 0.9)*.
Treatment 
group
Baseline FBG 
(mmol/L)
After 3 
months
After 6 
months*
After 9 
months
After 12 
months P value
Group 1 11.4 (3.2) 12.2 (4.5) 8.8 (13) 8.3 (6) 9.4 (1.8) >0.05
Group 2 9.7 (2.6) 8.0 (3.1) 8.1 (1.8) 8.6 (0.8) 7.1 (2.1) >0.05
Group 3 11.9 (4.0) 10.0 (3.7) 10.5 (1.5) 5.9 (0.9) 7.2 (0.07) >0.05
Group 4 12.2 (4.9) 10.0 (3.2) 7.7 (1.4) 9.7 (1.3) 8.3 (0.9) >0.05
Table 5. The change in fasting blood glucose (FBG) from baseline among the different treatment groups. 
Baseline to 6 months between-groups change in FBG (P = 0.8)**.
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as a single therapy or in combination with other agents40. In another perspective, Vivian noted that dapagliflozin 
is recommended as an adjunct to diet and exercise to improve glycemic control41. In this retrospective study, 
information on the diet and physical activities of the patients was not available due to the retrospective nature of 
the study. The results of this study revealed that dapagliflozin significantly improved the glycemic control of Qatari 
type 2 diabetic patients when used in combination with standard therapy. The maximum HbA1c reduction of 1.5 
percentage points was observed at 12 months, while a significant reduction of 1 percentage point was observed 
at 6 months from baseline. Fasting blood glucose was reduced started after 6 months of treatment by −2.9 mg/
dl (25%). A study by Iijima and coworkers showed that dapagliflozin improved blood glucose levels significantly 
and worked well in poorly controlled T2-DM patients with glimepiride42. In our study, many patients were on 
glimepiride. Another study in Korea also demonstrated the significant addition of dapagliflozin to an existing 
drug regimen43. The authors also indicated that the use of dapagliflozin as an add-on therapy could be a good 
alternative for patients who hesitate to use insulin therapy. Notably, the coadministered antidiabetic medications 
did not influence the reduction in either HbA1c or FBG. Our study was inconsistent with several other studies.
In a randomized study on T2-DM patients who were randomly given dapagliflozin, metformin extended 
release, or placebo for 12 weeks, List et al. found that at the end of the 12 weeks, dapagliflozin induced moderate 
glucosuria and a significant improvement in the glycemic index. In this study, they established that urinary excre-
tion of 200–300 kcal/day (glucose) is associated with a reduction in HbA1c of 0.5 to 0.9 percentage points and in 
FBG by 13 to 16 mg/dL from baseline37. Additionally, a group of studies evaluated dapagliflozin in combination 
with metformin slow/extended release32,37, glimepiride32,38, pioglitazone13, sitagliptin21, exenatide44 and saxaglip-
tin45. These studies reported a significant reduction in HbA1c. Moreover, dapagliflozin maintained its efficacy in 
controlling type 2 diabetic patients on insulin and contributed to reducing their total daily insulin requirement 
by 50%29.
The current study did not include dapagliflozin as a single agent. In a double-blinded, placebo-controlled 
phase-3 trial, Ferrannini et al. administered dapagliflozin as monotherapy to 485 patients inadequately controlled 
by diet and exercise, with HbA1c between 7.0 and 10%13. The patients were randomly assigned to receive pla-
cebo or dapagliflozin (2.5, 5, or 10 mg) once daily for 24 weeks. The reduction at the 24th week in HbA1c from 
the baseline was found to be −0.23 percentage points with the placebo and −0.58, −0.77, and −0.89 percent-
age points (p = 0.0005, p = 0.0005, and p < 0.0001 respectively) with 2.5, 5 and 10 mg dapagliflozin, respectively. 
Future studies in Qatar should examine the effectiveness of dapagliflozin as a single therapy.
Although this retrospective study has indicated several significant findings about dapagliflozin, it has some 
limitations. The patients’ adherence to medication regimen, diet and lifestyle behaviors cannot be measured or 
followed. The sample size might be too small to confidently generalize the results to all populations who received 
this drug. Additionally, based on the sample selected, all patients included were Qataris; this fact again affects the 
generalizability of the results. Despite these limitations, the study has proven that dapagliflozin provides an addi-
tional benefit to the reduction in HbA1c and FBG among T2-DM patients in Qatar. Future research should focus 
on longitudinal follow-up studies with larger sample sizes and inclusion of other segments of the population.
Conclusion
Dapagliflozin significantly reduced the HbA1c level and FBG of type 2 diabetes patients as add-on therapy, 
regardless of the type of the coadministered OHA or insulin within a 6-month treatment period.
Methods
Study Design. This study is a retrospective before-and-after observational study conducted at Hamad 
General Hospital (HGH), a tertiary teaching hospital in Qatar. Patients were identified via automated reports 
generated through the pharmacy dispensing system. All consecutive patients who obtained dapagliflozin from 
HGH pharmacies during the 2-year time frame from 1 April 2013 until 30 April 2015 were evaluated based on the 
inclusion and exclusion criteria by reviewing the computerized patient profile system, i.e., eMR-viewer.
Ethical approval. The study proposal has been reviewed and approved by the Medical Research Center 
(MRC), an Institutional Review Board at Hamad Medical Corporation (the research ID number is # 15292/15). 
All methods were performed in accordance with the relevant guidelines and regulations of Hamad Medical 
Corporation. The ethics committee waived the need to obtain informed consent for this study.
Study population. All adult diabetic patients who had obtained dapagliflozin from HGH pharmacies during 
the period of 1 April 2013 to 30 April 2015 were included. Patients were excluded if they were younger than 18 
years old, stopped their medication before completing one year, or had inadequate follow-up data.
Eighty-one patients were selected and followed up at 3, 6, 9 and 12 months. Patients were divided into four 
groups based on the most common antidiabetic medication combinations:
 (i) Group 1: Dapagliflozin + Metformin + Sulfonylureas (SUs) +/− DDP4i;
 (ii) Group 2: Dapagliflozin + Metformin + DDP4i +/− Insulin;
 (iii) Group 3: Dapagliflozin + Insulin + others; and
 (iv) Group 4: other combinations: Dapagliflozin + (Acarbose, Repaglinide, Liraglutide or Pioglitazone).
Study tool. The computerized patient medical profile was accessed to retrieve patient data after receiving 
ethical approval using a data collection sheet designed prior to the study.
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Data collection procedure. Data regarding prescribed drugs were obtained from the pharmacy dispensing 
system. Demographic information and laboratory results were obtained from the patient’s computerized profile 
(eMR-viewer). The period of treatment was determined from the first prescription dispensed from the pharmacy. 
The data collected included demographics, complete blood count, urea and electrolyte (baseline and follow-up), 
renal function (baseline and follow-up), duration of treatment, concomitant medications and any discontinuation 
of treatment.
Statistical analyses. Descriptive statistics were applied to present the demographics and baseline statistics. 
For the continuous variables, the mean (SD) or median (IQR) was reported. The categorical data were reported 
as frequencies and percentages. Data normality was evaluated by the Shapiro–Wilk test. Changes in the mean 
HbA1c and FBG over the four time points for the normally distributed data were analyzed using repeated meas-
ures ANOVA. The paired sample correlation test was carried out to identify points of significant change from 
baseline. A 95% confidence interval was reported, and a p value ≤ 0.05 was considered indicative of significance 
unless otherwise noted. Data analysis was performed using SPSS® version 23 (IBM Corp. Released 2013. IBM 
SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp) in all analyses.
Ethical approval. This study was approved by the Institutional Review Board at the Medical Research Center 
of Hamad Medical Corporation.
Informed consent. Informed consent was not applicable; data were obtained from the medical records.
Data Availability
Data are available upon request.
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